Press releases

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday,...

Acquisition intended to expand neuromodulation portfolio to provide more treatment options for people living with chronic low back pain MARLBOROUGH, Mass., Sept. 19, 2023 /PRNewswire/ -- Boston...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific...

Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 20, 2023, between...

Noninferiority established through high treatment success, low adverse event rates Findings presented at ESC Congress 2023 and simultaneously published in The New England Journal of Medicine...

First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems MARLBOROUGH, Mass., Aug. 8, 2023 /PRNewswire/ -- Boston...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis, 12.0 percent on an operational1 basis...

Boston Scientific Position on FDA Update About Use of Paclitaxel-Coated Devices to Treat Peripheral Arterial Disease On July 11, 2023, the U.S. Food and Drug Administration (FDA) published a...

MARLBOROUGH, Mass., Jul. 11, 2023 -- Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration (FDA) approval for the Vercise™ Neural Navigator 5 Software,...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2023 on Thursday, July 27,...

Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Jessica L. Mega and Susan E. Morano to its board of directors, each effective immediately. Dr. Mega is the co-founder...

Boston Scientific Corporation (NYSE: BSX) announced today that its Series A 5.50% Mandatory Convertible Preferred Stock (the preferred stock) will automatically convert into shares of the...

Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System* Results from global trial of the POLARx™...

Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023. Mike Mahoney, chairman and chief executive officer,...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational1 basis...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2023 on Wednesday, April 26,...

Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference on Wednesday, March 1, 2023. Dan Brennan, executive vice president...

New technology designed to help inform real-time clinical decisions during kidney stone procedures MARLBOROUGH, Mass., Feb. 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and...

Boston Scientific Corporation (NYSE: BSX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San Francisco, California. Mike Mahoney, chairman...

Boston Scientific Corporation (NYSE: BSX) and Acotec Scientific Holdings Limited ("Acotec" and 6669.HK) announced today that Boston Scientific will make a partial offer to acquire a majority...

Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass., Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation...

Boston Scientific Corporation (NYSE:BSX) has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2TM Aortic...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On November 15, 2022, Dan Brennan, executive vice president and chief financial officer, and Lauren...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.170 billion during the third quarter of 2022, growing 8.1 percent on a reported basis, 13.7 percent on an operational1 basis and...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2022 on Wednesday, October...

Marlborough, Mass., September 19, 2022 — Boston Scientific Corporation (NYSE: BSX) announces the appointment of Kathryn Unger as vice president, Environmental, Social and Governance (ESG)....

Results from largest randomized TAVR trial to date presented at TCT 2022 MARLBOROUGH, Mass., Sept. 17, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has announced results from the...

WATCHMAN FLX now the only LAAC technology in the United States that allows for either DAPT or OAC immediately following implantation MARLBOROUGH, Mass., Sept. 6, 2022 /PRNewswire/ -- Boston...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor events. On Wednesday, September 7, 2022, Mike Mahoney, chairman and chief executive officer, and Lauren Tengler,...

Company to add novel technology cleared for use in peripheral vasculature to interventional oncology and embolization portfolio MARLBOROUGH, Mass., Aug. 15, 2022 /PRNewswire/ -- Boston Scientific...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.244 billion during the second quarter of 2022, growing 5.4 percent on a reported basis, 9.6 percent on an operational1 basis and...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2022 on Wednesday, July 27,...

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Synergy Innovation Co., Ltd, to purchase its majority stake (approximately 64...

Boston Scientific Corporation (NYSE: BSX) will participate in Bank of America's Global Healthcare Conference on Thursday, May 12. Dan Brennan, executive vice president and chief financial officer, and

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EMBOLD™ Fibered Detachable Coil,...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis...

Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for its latest image guided...

Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2022, on Wednesday, April 27,...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the pricing terms of the previously announced upsized cash tender offer (the "Tender Offer") for $2,852,561,000 in...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $2.5 billion aggregate...

Boston Scientific Corporation (NYSE: BSX) (the "Company") today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of...

Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the commencement of a cash tender offer (the "Tender Offer") for up to $2.5 billion aggregate principal amount (the...

Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device....

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as...

Boston Scientific Corporation (NYSE: BSX) will participate in SVB Leerink's 11th Annual Global Healthcare Conference on Thursday, February 17, 2022. Dan Brennan, executive vice president and chief...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.127 billion during the fourth quarter of 2021, growing 15.4 percent on a reported basis, 16.9 percent on an operational1 basis...

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at the 25th North American Neuromodulation Society (NANS) annual meeting, in Orlando, Florida, on...

Boston Scientific Corporation (NYSE: BSX) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022. Mike Mahoney, chairman and chief executive officer,...

Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On November 15, 2021, Dan Brennan, executive vice president and chief financial officer, and Lauren...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and...

October 20, 2021 – Boston Scientific Corporation announces that it reached a settlement with Micro-Tech Endoscopy resolving claims of patent infringement by Boston Scientific against Micro-Tech...

Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at...

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to...

Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular...

Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2021 on Wednesday, October...

Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The innovative non-console and lytic-free...

Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment) successfully met both primary endpoints,...

Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 22, 2021, from 8:30...

Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model B Single-Use Bronchoscope, designed for use in bedside...

Boston Scientific Corporation (NYSE: BSX) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and...

Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for single-use duodenoscopes, applicable to the...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported basis, 49.6 percent on an operational1 basis...

Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2021 on Tuesday, July 27, 2021...

Boston Scientific Corporation (NYSE: BSX) announced today the election of David S. Wichmann to its board of directors, effective immediately. Wichmann recently served as chief executive officer of...

Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific...

Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use device designed for bedside procedures in the...

Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 37th Annual Strategic Decisions Conference on Friday, June 4, 2021. Mike Mahoney, chairman and chief executive officer,...

Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance, including low rates of paravalvular leakage (PVL) and...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On May 11, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa,...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ending March 31, 2021 on Wednesday, April 28,...

Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a type of radioembolization comprised of...

Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On February 25, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System. The...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately-held company which offers a full portfolio of...

Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) systems. The unified portfolio of four MRI conditional,...

Boston Scientific Corporation (NYSE: BSX) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71 billion during the fourth quarter of 2020. This...

Boston Scientific Corporation (NYSE: BSX) will participate in the virtually held 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Mike Mahoney, chairman and chief...

Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO) patent infringement case against Boston Scientific in...

MARLBOROUGH, Mass., December 2, 2020 – Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator...

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1. Mike Mahoney, chairman and chief executive officer, and Susie...

Boston Scientific Corporation (NYSE: BSX) has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic Valve System due to complexities associated...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On November 12, 2020, Meghan Scanlon, senior vice president and president, Urology and...

Boston Scientific (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, developed for the treatment of patients with...

Boston Scientific Corporation (NYSE: BSX) has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device within...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.659 billion during the third quarter of 2020. This represents a decline of (1.8) percent on a reported basis, (2.5) percent on an...

Boston Scientific Corporation (NYSE: BSX) will webcast an investor update at the virtual 2020 Transcatheter Cardiovascular Therapeutics (TCT) on Thursday, October 15 from 1:00 – 2:00 p.m. EDT....

Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditionali,...

Boston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Europe. This next-generation transcatheter aortic valve...

Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed...